Voice of the Patient: Supporting FDA As Well As Educating FDA
This article was originally published in RPM Report
The Food & Drug Administration’s patient-focused meetings are primarily listening sessions for the agency drug reviewers involved. But the FDA participants can go the next step and ask the patients for help with public debates. That happened at a recent session with fibromyalgia patients.
You may also be interested in...
While pain and fatigue are well-recognized symptoms of fibromyalgia, patients testifying at the PDUFA V disease area meeting gave FDA drug review staff insight into other health effects, such as visual disturbances.
FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.